Mikihiro Yunoki

Suita, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Anti-monkeypox virus-neutralizing activities of human immunoglobulin manufactured between 1999 and 2021 and derived from donors in the United States and Japan.

Anti-monkeypox virus-neutralizing activities of human immunoglobulin manufactured between 1999 and 2021 and derived from donors in the United States and Japan.

Journal: Vox sanguinis
Published: January 29, 2024

Changes in Anti-SARS-CoV-2 Antibody Titers of Pooled Plasma Derived From Donors in Japan: A Potential Tool for Mass-Immunity Evaluation.

Changes in Anti-SARS-CoV-2 Antibody Titers of Pooled Plasma Derived From Donors in Japan: A Potential Tool for Mass-Immunity Evaluation.

Journal: The Journal of infectious diseases
Published: January 13, 2023

Decline in intravenous immunoglobulin titer against influenza virus A/H2N2 derived from donors in Japan.

Decline in intravenous immunoglobulin titer against influenza virus A/H2N2 derived from donors in Japan.

Journal: Journal of medical virology
Published: November 20, 2022

Long-term monitoring of antibody titers against microorganisms in human intravenous immunoglobulin lots derived from healthy donors in Japan manufactured during 1998-2018.

Long-term monitoring of antibody titers against microorganisms in human intravenous immunoglobulin lots derived from healthy donors in Japan manufactured during 1998-2018.

Journal: Transfusion
Published: March 02, 2022

Screening for parvovirus B19 antigen through chemiluminescent enzyme immunoassay is equivalent to B19 nucleic acid amplification test-based screening of pooled plasma.

Screening for parvovirus B19 antigen through chemiluminescent enzyme immunoassay is equivalent to B19 nucleic acid amplification test-based screening of pooled plasma.

Journal: Transfusion
Published: February 26, 2021

Assessment of the potentially decreased neutralizing activities of intravenous immunoglobulin against future coronavirus variants.

Assessment of the potentially decreased neutralizing activities of intravenous immunoglobulin against future coronavirus variants.

Journal: Transfusion
Published: February 09, 2021

Virus Neutralization by Human Intravenous Immunoglobulin Against Influenza Virus Subtypes A/H5 and A/H7.

Virus Neutralization by Human Intravenous Immunoglobulin Against Influenza Virus Subtypes A/H5 and A/H7.

Journal: Biologics : targets & therapy
Published: November 12, 2020

Polyethyleneimine-modified resins effectively remove porcine circovirus and cellular prion protein.

Polyethyleneimine-modified resins effectively remove porcine circovirus and cellular prion protein.

Journal: Journal of virological methods
Published: October 08, 2020

Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan.

Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan.

Journal: Transfusion
Published: July 27, 2020

Long-term monitoring of virus antibody titers in human intravenous immunoglobulin lots derived from donors in Japan.

Long-term monitoring of virus antibody titers in human intravenous immunoglobulin lots derived from donors in Japan.

Journal: Transfusion
Published: February 28, 2018

Successful removal of porcine circovirus-1 from immunoglobulin G formulated in glycine solution using nanofiltration.

Successful removal of porcine circovirus-1 from immunoglobulin G formulated in glycine solution using nanofiltration.

Journal: Biologicals : journal of the International Association of Biological Standardization
Published: July 27, 2017

Neutralizing activities against seasonal influenza viruses in human intravenous immunoglobulin.

Neutralizing activities against seasonal influenza viruses in human intravenous immunoglobulin.

Journal: Biologics : targets & therapy
Published: March 24, 2017
Showing 1-12 of 19

Last Updated: 09/26/2026